牛津Cardiomox是一家总部位于英国的高科技公司，专注于开发用于非侵入性心脏病诊断的先进医疗设备和软件。他们的研究使他们能够制造出新一代的磁心电图(MCG)医疗设备，这些医疗设备带有极其灵敏的超导体量子干涉装置(SQUID)传感器，可以在无遮挡的医院环境中绘制出胸腔内非常微弱的生物磁信号，而无需与病人接触。
Oxford Cardiomox is an UK-based high-tech company focused on developing pioneering medical devices and software for non-invasive heart disease diagnosis. Their research has enabled them to manufacture a new generation of magnetocardiography (MCG) medical devices with the extremely sensitive superconductor quantum interference device (SQUID) sensors to map the very weak bio-magnetic signals in the thorax in an unshielded hospital environment without any contact with patients.
通过开发和实施创新的物理和计算方法，牛津Cardiomox能够生成电流密度矢量图，以成像心脏的电生理状态，更具体地说，是心脏磁场中的扰动，是心脏病的症状。由于MCG在临床应用方面有着悠久的历史，牛津Cardiomox的技术在为患者提供诊断方面有着良好的记录，证明了MCG作为一种新的心脏病学革命性方法的力量。发明者已经提交了四项关键的专利申请。这些申请是在2011-2012年进行的，都处于PCT阶段。Cardiomox是这些专利在全球的独家授权用户。
By developing and implementing innovative physical and computational methods, Oxford Cardiomox is able to generate current density vector maps to image the heart’s electrophysiological state, more specifically the perturbation in the heart’s magnetic field, symptomatic of cardiac disease. With a strong history in the application of MCG in a clinical setting, Oxford Cardiomox’s technology has an established track record in providing diagnostics for patients, demonstrating the power of MCG as a new revolutionary method in cardiology. The inventors have filed four key patent applications. These filings were made in 2011-2012 and are all the at PCT stage. Cardiomox is the exclusive licensee of those patents globally.
Cardiomox MCG-9能够在早期进行心血管诊断，在过去的20年里，心脏起搏器在临床应用中发挥了关键作用。Sosnytskyy等人在2013年的研究中发现，MCG在健康患者、心肌炎或缺血性心脏病患者之间具有高度特异性和高敏感性的明确区分，使其成为一种强有力的心脏病诊断工具。对该技术及其基础科学进展的深刻理解是有效医疗创新发展的关键。因此，Cardiomox的MCG-9结合了有效的屏蔽、场补偿和梯度采集来进行高度敏感和精确的测量。
Cardiomox MCG-9 enabling cardiovascular diagnostics at an early stage, working with pioneering researchers, who have played a key role in developing MCG for clinical applications in the last 20 years, Cardiomox has a strong technical and scientific background. In 2013, Sosnytskyy et al., showed that MCG allowed a clear distinction with high specificity and high sensitivity between healthy patients, subjects with either myocarditis or with ischemic heart disease, making it a powerful diagnostic tool for heart conditions. A strong understanding of the technology and its underpinning scientific advances are key to the development of effective medical innovations. As a result the MCG-9 from Cardiomox combines effective shielding, field compensation and gradiometric pick up for highly sensitive and accurate measurements.
